# 2025 HALF YEAR RESULTS AND ACQUISITION OF ORTHOLITE HOLDINGS LLC





### **AGENDA**

Highlights

OrthoLite Acquisition

Financial Performance

Outlook

Appendices



### HIGHLIGHTS

### GAINING SHARE IN UNCERTAIN MARKETS, MARGIN EXPANSION AND STEP-UP IN FREE CASH FLOW GENERATION



CER revenue up 2%<sup>1</sup>, good growth in January-April, followed by increased market uncertainty

Continued outperformance – market share gains in Apparel & Footwear

Increased Group adjusted EBIT margin of 19.8%<sup>1</sup>, within 19-21% medium term range

Completed exit from Performance Materials' North American Yarns business in June

Clear global market leader in 100% recycled thread products – revenue +73% to \$269m

Sales in organic adjacencies up 30% year on year, supporting revenue acceleration

Definitive agreement to acquire 100% of OrthoLite Holdings LLC for a \$770 million enterprise value

# ACQUISITION OF ORTHOLITE THE MARKET LEADER IN INSOLE TECHNOLOGY



### **ORTHOLITE AT A GLANCE** GLOBAL LEADER OF INSOLE OPEN-CELL FOAM TECHNOLOGY FOR LEADING BRANDS





#### OrthoLite's global operating footprint<sup>2</sup>



Reflects production facilities and sales offices.

3 Four facilities operated by licensing partner.

2

# COATS Comfort foam insoles

# **TRANSACTION HIGHLIGHTS**

### ACCELERATING FOOTWEAR GROWTH STRATEGY THROUGH \$770M COMBINATION WITH MARKET LEADER IN INSOLE TECHNOLOGY

Key highlights						
Exceptional Opportunity	Growth Accelerator	Growth Accelerator Strong St		rategic Fit Improves Portfolio Qu		Funding Proposition
Creating a market-leading Super Tier 2 supplier of critical footwear components	OrthoLite exposed to an expanding TAM in faster growing market	a faster		High growth and margin Footwear division becomes a materially larger segment of the group		20% equity placing and debt; net leverage expected to fall below 2x by end of 2026
OrthoLite - a high growth, quality asset through the cycle				Benefits of	f the com	bination
8% Revenue growth <sup>1</sup>	90%- Operating cash	-	Coats F	.\$700m Footwear FY24 rma revenue		EPS accretive From first full year
26% FY24 EBIT margin	c.36% Market sl		\$20m Joint cost synergies to be delivered by 2028		By th	ROIC > WACC hird year (FY28) at latest

2 Last three years 2022-2024.

3 OrthoLite market share of open cell insoles (pairs).

# **STRATEGIC RATIONALE**

### COMBINING MARKET LEADING PLATFORMS TO CREATE A HIGH GROWTH MARKET LEADER

		COATS Footwear	🗱 Ortholite	Strategic rationale
1	Creating a 'Super Tier 2' in the footwear segment	<b>#1</b> Global #1 in threads Global #1 structural components	<b>#1</b> Global #1 open-cell foam insoles	Greater scale, deep brand intimacy; enhanced innovation and sustainability
2	Strong customer relationships	c.350 brand partners 29% market share <sup>1</sup>	c.550 brand partners c.36% market share <sup>2</sup>	Further access to brands and Tier 1s - additional opportunities
3	Clear product category leaders	<ul> <li>✓ Quality</li> <li>✓ Sustainability</li> <li>✓ Innovation</li> </ul>	<ul> <li>✓ Quality</li> <li>✓ Sustainability</li> <li>✓ Innovation</li> </ul>	Strong alignment on key growth enablers
4	Synergy optimisation	Strong track record of M&A integration	Geographic footprint overlap Consolidation opportunities	Initial \$20m joint cost synergies; significant revenue synergy potential
5	Attractive financial profile	<b>24-26%</b> EBIT margins <sup>3</sup>	>26% EBIT margins⁴	Margin accretive business

© Coats Source: OrthoLite's Confidential Information Presentation, Coats FY24 Results.

1 Coats' Footwear market share

2 OrthoLite market share of open cell insoles (pairs).

3 Coats' Footwear medium-term targets.

4 OrthoLite medium-term targets.

### **CREATING A SUPER TIER 2 SUPPLIER** EXCEPTIONAL OPPORTUNITY TO COMBINE COMPLEMENTARY BUSINESSES



### HIGHLY COMPLEMENTARY BUSINESSES ALIGNED COMMERCIAL AND OPERATIONAL GLOBAL FOOTPRINTS, WITH COMMON APPROACH TO EXECUTION



# **SIGNIFICANT VALUE CREATION**

### **\$20M IDENTIFIED JOINT COST SYNERGIES, ALONGSIDE ENHANCED GROWTH OPPORTUNITIES**

	Sources of joint cost synergies	Sources of growth synergies		
Initial \$20m annual full benefit cost synergies by FY28 for c.\$35m one-off cost		Additional upside potential		
Operational Management	Footprint optimisation Operational excellence and automation	Innovation acceleration		
Procurement	Strategic procurement Direct and indirect cost focus	Cross-sell / Up-sell opportunities		
Support Functions	Cost optimisation Supported by phased ERP implementation	Cirql upside potential		

# **COMPELLING FINANCIAL RATIONALE**

### ATTRACTIVE TRANSACTION RETURNS, ALONGSIDE ACCELERATED DELIVERY OF GROUP **FINANCIAL GOALS**

	Initial	Post synergy	Acceleratin	g Coats' existing medium term targets <sup>4</sup>
Valuation	10.0x LTM EV/EBITDA <sup>1</sup>	< 8.0x LTM EV/EBITDA <sup>1,2</sup>		Revenue CAGR > 5%
EPS accretion	Low Single Digit in FY26	High Single Digit <sup>3</sup>		
Margin enhancement	95bps proforma⁵	c.200bps		EBIT margin 19-21%
Cash generation	90%+ operating	cash conversion		<b>EPS CAGR &gt; 10%</b>
Leverage	2.2x proforma Dec 25	< 2.0x Dec 26		
ROIC	ROIC > WACC by FY28 and cor	mpounding further with growth		\$750m free cash flow (cumulative)
na	Additional \$10m earn-out cons			

payable based on FY25 EBITDA performance between \$80m to \$84m

EBITDA is LTM adjusted. © Coats 1

- 2 EV/EBITDA multiple paid post earnout.
  - EPS accretion includes \$20m full benefit synergies from FY28. 3

- 4 Set in March 2025 (FY24 results). FCF for 5-year period. 5
  - Accretion to Coats group.



### A PROVEN FORMULA FOR SUCCESSFUL M&A STRONG TRACK RECORD OF DELIVERY BY AN EXPERIENCED TEAM



# FINANCIAL PERFORMANCE





3

Net debt excludes leases



© Coats Source: Coats H1 25 Results.

1 Income statement figures exclude discontinued operations (US Yarns).

2 Free cash flow pre-dividend

# **KEY FINANCIAL METRICS**

### **ACCELERATED MARGIN AND FCF GROWTH**

	H1 2025	H1 2024 <sup>1</sup>	Reported change	H1 2024 CER	CER <sup>2</sup>
Revenue (\$ million)					
Apparel	381	376	2%	369	3%
Footwear	199	198	1%	198	1%
Performance Materials	125	131	(4%)	128	(2%)
Group	705	704	0%	695	2%
Adj. EBIT (\$ million)					
Apparel	78	72	9%	70	11%
Footwear	48	48	1%	48	1%
Performance Materials	14	14	0%	13	4%
Group	140	133	5%	131	7%
Adj. EBIT margin (%)					
Apparel	20.5%	19.1%	140 bps	19.0%	140 bps
Footwear	24.1%	24.1%	0 bps	24.0%	10 bps
Performance Materials	11.1%	10.6%	50 bps	10.4%	60 bps
Group	19.8%	18.9%	90 bps	18.9%	100 bps
Adj. EPS (cents)	4.7	4.5			
FCF pre shareholder dividend (\$ million)	54	39			
Interim dividend per share (cents)	1.0	0.93			

# **INCOME STATEMENT**

### **7% CER EBIT GROWTH**

#### **Exceptional / acquisition related items**

- Strategic projects \$1m
- Acquisition related items \$10m

#### **Finance costs**

- Slight increase due to H2 2024 UK pension buy-in payments
- Good cash management partially offsets

#### Underlying effective tax rate 29% (2024 29%)

- In line with guidance
- Full year expectations remains at 29%

#### **Discontinued operations**

Exit from NA Yarns

#### Dividend

Interim dividend of 1.00 cent per share, up 7.5% vs 2024

1. Numbers are reported

2. Restated to exclude discontinued operations, where relevant

\$m	<b>2025 H1<sup>1</sup></b>	<b>2024 H1</b> <sup>2</sup>
Adjusted EBIT	140	133
Exceptional / acquisition related items	(11)	(12)
EBIT	128	121
Share of profit from JVs	1	1
Finance costs	(18)	(16)
Profit before tax	111	106
Тах	(34)	(31)
Profit from continuing operations	77	75
Discontinued operations	(7)	(2)
Profit for the period	70	73
Minority interest	(11)	(13)
Attributable profit	59	60
Adjusted EPS (cents)	4.69	4.51
EPS (cents)	4.09	3.89
Interim DPS (cents)	1.00	0.93

# **CASH FLOW AND LEVERAGE**

### **STRONG CASH GENERATION**

### H1 2025 CASHFLOW (\$m)



Free cash flow pre-dividend was \$54m, up from \$39m

Minimal net exceptional cash flows (incl. discontinued)

Leverage of 1.4x remains comfortably within 1-2x range. Net debt \$430m (excl. leases)

\$m	2025 H1	2024 H1
Adjusted free cash flow	51	66
Exceptional, discontinued operations and other	2	(27)
Free cash flow pre-shareholder dividend	54	39
Dividends paid to equity shareholders	(35)	(31)
FX and other movements	(1)	(2)
Movement in leases (IFRS 16)	14	0
Change in net debt (incl IFRS 16)	31	6
Group net debt (excl IFRS 16)	(430)	(381)
Leases (IFRS 16)	(71)	(85)
Group net debt (incl IFRS 16)	(501)	(465)
Proforma leverage (excl IFRS 16)	1.4x	1.4x







# APPENDICES



# **GROUP OPERATING PROFIT AND MARGIN**

**POSITIVE PRICE/MIX, AND CONTINUED BENEFITS FROM STRATEGIC PROJECTS AND SYNERGIES** 



# **DIVISIONAL MARGINS**

### **APPAREL AND FOOTWEAR MARGINS ACHIEVED MEDIUM TERM TARGETS**



#### Apparel margin up 140bps YOY to 20.5%

- Achieved medium-term target margin target of >19%
- 140bps higher at CER driven by price and mix, benefits
- Ongoing procurement benefits and cost control

#### Strong Footwear margin maintained at 24.1%

- In line with medium-term margin target of 24-26%
- Strong commercial delivery, benefits from synergies and footprint consolidation

#### PM margin up 50bps YoY to 11.1%

- Restated for exit of North American Yarns business; improved margin by c. 230bps
- Reflects operational improvements across division

### SUSTAINABILITY: A KEY COMMERCIAL DIFFERENTIATOR AT THE HEART OF OUR BUSINESS

	Pillar	Metric	2022 Baseline	H1 25 ACTUAL	2026 TARGET	
	ENERGY	Reduction in Scope 1&2 emissions	182 kTonnes <sup>1</sup>	36% reduction	22% reduction from 2022 baseline	
X	MATERIALS	% non-virgin oil-based materials	28% <sup>2</sup>	51%	60%	
٥٥٥	WATER	Increase in Water Recycling Rate	24%1	24% increase	33% increase from 2022 baseline	
		Waste to Landfill	2,278 tonnes <sup>1</sup>	Zero <sup>4</sup>	Zero	
15/8	C2 WASTE	Effluent Compliance (Roadmap to Zero Programme)	99.76%	99.92%	100%	
	PEOPLE	GPTW coverage	GPTW coverage	86%	87% <sup>3</sup>	88%
57		Women in leadership roles	21%	31%	30%	

1.Baseline restated to reflect 2023 divestments. 2. Baseline restated from 25% to reflect reclassification of certain materials,. 3. 2025 GPTW results available in H2: percentage refers to H2 2024 results

4. Excluding small amounts of controlled landfill disposal for materials such as asbestos or medical waste in geographies where this is a no-option regulatory requirement

© Coats

TR	TRANSACTION STRUCTURE AND KEY DETAILS				
		Key details			
1	Accelerate Placing	<ul> <li>Non pre-emptive placing of up to 19.99% of issued share capital</li> <li>Offer to US QIBs under Rule 144A</li> <li>RetailBook offer of up to GBP equivalent of €8m</li> <li>Pricing to be determined at the end of the bookbuild</li> <li>Equity raise is not conditional on the acquisition completing</li> </ul>			
2	Use of Proceeds	<ul> <li>To fund transaction Enterprise Value of \$770m</li> <li>Additional contingent earnout consideration of up to \$10m payable based on EBITDA performance in 2025 between \$80m to \$84m</li> </ul>			
3	Directors Participation	Directors will demonstrate their support with a meaningful participation, expected to be over £500,000 collectively			
4	Timetable	<ul> <li>Targeted launch: after market close, Wednesday 16<sup>th</sup> July</li> <li>Simultaneous announcement of 2025 interim results, acquisition and placing expected after market close on 16th July</li> <li>Admission of shares and settlement expected on 21st July</li> </ul>			
5	Joint Bookrunners	<ul><li>BNP Paribas</li><li>Peel Hunt</li></ul>			

## **DISCLAIMER (1/4)**

#### INVESTOR PRESENTATION DISCLAIMER

THIS PRESENTATION, ITS CONTENTS AND ANY INFORMATION PROVIDED IN THIS PRESENTATION ARE STRICTLY CONFIDENTIAL AND ARE FOR INFORMATION PURPOSES ONLY AND MUST NOT BE RELIED UPON FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (EXCEPT TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN RULE 144A OF THE U.S. SECURITIES ACT OF 1933, AS AMENDED), CANADA (EXCEPT TO THOSE WHO ARE ACCREDITED INVESTORS AND PERMITTED CLIENTS), AUSTRALIA, JAPAN, SOUTH AFRICA, OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION OR PERSON WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESENTATION IS NOT AND DOES NOT FORM A PART OF AN OFFER OR INVITATION TO BUY OR SELL SECURITIES. IN REVIEWING THIS INFORMATION, YOU ARE ACKNOWLEDGING THE CONFIDENTIAL NATURE OF THIS INFORMATION AND ARE AGREEING TO ABIDE BY THE TERMS OF THIS DISCLAIMER.

This Presentation has been prepared by Coats Group plc (referred to herein as "Coats" or the "Company") solely for informational purposes. For the purposes of this notice, "the Presentation" shall mean and include the slides that precede this notice, this document, the oral presentation of the slides by the Company or any person on behalf of the Company, any audio-visual materials, its contents or any part of it, any question-and-answer session that follows the oral presentation, hard copies of this document and any materials distributed at, or in connection with the oral presentation. By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation. You must keep this Presentation confidential. This Presentation has been prepared and issued by and is the sole responsibility of the Company and is being furnished to each recipient solely for its own information and in connection with the preliminary discussions in relation to the Company.

This Presentation is strictly confidential and may contain material non-public information that is price-sensitive in nature ("Inside Information"). By receiving this document, you agree that you may be given Inside Information and that you may be considered an "insider", and may have legal or regulatory obligations which may extend to restrictions on your ability to (i) trade in the Company's securities (or related investments, such as derivatives, whose price or value depends on the price or value of the Company's securities), (ii) disclose the Inside Information to anyone else, (iii) use the Inside Information, or (iv) do anything whilst in possession of it that encourages someone else to deal in the relevant securities (or related investments). Any such disclosure, dealing or encouraging others to deal on the basis of such Inside Information, may amount to insider dealing under the Criminal Justice Act 1993 and market abuse under the UK Market Abuse Regulation<sup>(1)</sup> or other applicable laws and/or regulations in other jurisdictions. These restrictions will continue until the information contained herein that is Inside Information is made publicly available or is no longer material or price sensitive. Accordingly, this document may not be copied, distributed, published, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient to any other person (whether within or outside such person's organisation or firm), for any purpose or under any circumstances.

This Presentation is not a prospectus for the purposes of the assimilated Regulation (EU) No 2017/1129 as it forms part of the law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"), Part VI of the Financial Services and Markets Act 2000 (the "FSMA") and the prospectus rules (as defined in section 73A(4) of the FSMA) of the Financial Conduct Authority (the "FCA") or otherwise and this Presentation has not been examined or approved by the FCA or any other regulatory authority. This Presentation is not intended to provide, and must not be taken as, the basis of any decision by an investor to subscribe for or purchase any securities and should not be considered as a recommendation to acquire any securities of the Company. The Company has not decided whether or not to proceed with any offering of securities or proposed application for admission of its securities to trading on a regulated market in the United Kingdom. The recipient must make its own independent assessment and such investigations as it deems necessary and is advised to conduct its own due diligence with respect to the Company

The information contained in this Presentation is strictly private and confidential and may not be reproduced, redistributed or disclosed in any way in whole or in part to any other person without the prior written consent of the Company. Save as set out below, this Presentation has been prepared on the basis of information held by the Company and also from publicly available information. This Presentation does not purport to contain all the information that may be required by the recipient to make an evaluation of the Company. The Company prepared this Presentation on the basis of information which it has and from sources believed to be reliable. To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are by reference to the time this Presentation was prepared and are subject to change without notice. Accordingly, no reliance should be placed on any of the information contained in this Presentation.

# **DISCLAIMER (2/4)**

None of the Company, BNP PARIBAS ("BNPP"), or Peel Hunt LLP ("Peel Hunt") nor any of such person's respective directors, officers, employees, agents, affiliates or advisors is under any obligation to update or keep current the information contained in the Presentation to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it and any opinions expressed in this Presentation are subject to change without notice. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future. This Presentation does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company's securities. Any investment decision to buy the Company's securities must be made solely on the basis of publicly available information.

The information contained in this Presentation is strictly private and confidential and may not be reproduced, redistributed or disclosed in any way in whole or in part to any other person without the prior written consent of the Company. Save as set out below, this Presentation has been prepared on the basis of information held by the Company and also from publicly available information. This Presentation does not purport to contain all the information that may be required by the recipient to make an evaluation of the Company. The Company prepared this Presentation on the basis of information which it has and from sources believed to be reliable. To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from official or third-party sources to a source of the company operates. While the Company believes that such research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are by reference to the time this Presentation was prepared and are subject to change without notice. Accordingly, no reliance should be placed on any of the information contained in this Presentation. None of the Company, BNP PARIBAS ("BNPP"), or Peel Hunt") nor any of such person's respective direct

None of BNPP, Peel Hunt or any of their respective directors, officers, employees, agents, affiliates and consultants ("Associates") or advisors have independently verified the information in this document and such information does not constitute a recommendation from either BNPP or Peel Hunt to you. None of BNPP, Peel Hunt or their Associates accepts any responsibility, obligation or liability whatsoever for, or makes any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of, the information in this Presentation or whether any information has been omitted from the Presentation or as to any other information relating to the Company, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation, its contents or otherwise arising in connection therewith. Each of BNPP, Peel Hunt and their Associates disclaims, to the maximum extent permitted by applicable law and regulation, all and any indirect or direct responsibility and liability whether express or implied, arising in tort, contract or otherwise, which they might otherwise have in respect of (i) this Presentation or any information contained therein and (ii) any errors, omissions or misstatements contained in this Presentation has not been independently verified. None of BNPP, Peel Hunt or their Associates shall have any liability whatsoever (in negligence or otherwise) for any other person by BNPP, Peel Hunt or their Associates in respect of the Presentation. No duty of care is owed or will be deemed to be owed to you or any other person by BNPP, Peel Hunt or their Associates in respect of the Presentation.

No representation or warranty, express or implied, is given by or on behalf of the Company or any of its parent or subsidiary undertakings or any of such person's respective directors, officers, employees, agents, affiliates or advisors as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of the information or opinions contained in this Presentation or otherwise made available nor as to the reasonableness of any information contained herein or therein and no responsibility or liability (including in respect of direct, indirect or consequential loss or damage) is assumed by any such persons for such information or opinions or for any errors or omissions. The recipient acknowledges that neither it nor the Company intends that the Company act or be responsible as a fiduciary to the recipient of this document or presentation, its management, stockholders, creditors or any other person. Each of the recipient and the Company by accepting and providing this Presentation respectively expressly disclaims any fiduciary relationship and agrees that the recipient is responsible for making its own independent judgments with respect to any transaction and any other matters regarding this Presentation.

The recipient should conduct its own independent investigation and assessment as to the validity of the information contained in this Presentation, and the economic, financial, regulatory, legal, taxation, stamp duty and accounting implications of that information. The recipient confirms that it is not relying on any recommendation or statement of the Company, BNPP, Peel Hunt or any of their Associates. The recipient is strongly advised to consult its own independent advisors on any economic, financial, regulatory, legal, taxation, stamp duty and accounting issues relating to the information contained in this Presentation.

# **DISCLAIMER (3/4)**

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections and opinions ("Forward Statements"), which are based on current assumptions and estimates by the management of Coats. These Forward Statements include all matters that are not historical facts. These Forward Statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. By their nature, Forward Statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Company. Past performance cannot be relied upna as a guide to future performance and should not be taken as a representation that trends or activities underlying past performance will continue in the future. No representation or guarantee is given that the assumptions disclosed in this Presentation upon which Forward Statements may be based are reasonable. The recipient acknowledges that circumstances may change, and the contents of this Presentation, and have not been audited or otherwise independently verified, and will not publicly release any revisions that may be made to these Forward Statements, which may result from events or circumstances arising after the date of this Presentation. No statement in this Presentation is intended to be a profit forecast. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. In addition, even if the results of operations, financial condition and liquidity of the Company, and the development of the industry in which the Company operates, are consistent with the Forward Statements. In addition, even if the results of operations, financial condition and liquidity of the company of the company or any other person.

In particular, no statement in this Presentation is intended to be a profit forecast and no statement of a financial metric should be interpreted to mean that any financial metric for the current or future financial years would necessarily match or exceed the historical published position of the Group. The estimates set out in the Presentation have been prepared based on certain assumptions and forecasts, including those set out in this Presentation, some of which are outside of the Company's influence and/or control, and is therefore inherently uncertain and there can be no guarantee or assurance that it will be correct. The estimates have not been audited, reviewed, verified or subject to any procedures by the Company's auditors. You should not place undue reliance on them and there can be no guarantee or assurance that they will be correct.

BNP PARIBAS is authorised and regulated by the European Central Bank and the French Autorité de contrôle prudentiel et de résolution. BNP PARIBAS is authorised by the Prudential Regulation Authority (the "PRA") and is subject to regulation by the FCA and limited regulation by the PRA. BNP PARIBAS London Branch is registered in the UK under number FC13447. UK establishment number: BR000170. UK establishment office address: 10 Harewood Avenue, London NW1 6AA. Peel Hunt is authorised and regulated in the United Kingdom by the FCA. Peel Hunt is registered with registered number OC357088 and has its registered office at 7th Floor, 100 Liverpool Street, London EC2M 2AT, United Kingdom. Each of BNPP and Peel Hunt is acting exclusively for the Company and no one else in connection with this Presentation or any future transaction in connection with it. Each of BNPP and Peel Hunt will not regard any other person (whether or not a recipient of this Presentation) as a client and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or arrangement of securities of the Company referred to in this Presentation.

This Presentation is not and does not form part of an offer to sell or a solicitation of an offer to buy any securities and is not for publication or distribution in the United States or to any U.S. Persons (as defined below) except to QIBs (as defined below). The securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and in accordance with any applicable securities law of any state or other jurisdiction of the United States. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. This Presentation may not be viewed by persons within the United States or U.S. Persons(within the meaning of Regulation S under the Securities Act) other than "qualified institutional buyers" ("QIBs") (as defined in Rule 144A under the Securities Act) and in accordance with any applicable securities Iaw of any applicable securities Iaw of any state or other jurisdiction of the United States.

The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are "accredited investors" within the meaning of National Instrument 45-106 – Prospectus Exemptions (or section 73.3(1) of the Securities Act (Ontario), as applicable) (each, an "Accredited Investor") and "permitted clients" within the meaning of National Instrument 31-103 – Registration Requirements, Exemptions and Ongoing Registrant Obligations (each, a "Permitted Client"). Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Canadian purchasers are advised to seek legal advice prior to any contemplated purchase and resale of securities of the Company.

# **DISCLAIMER (4/4)**

Save as set out above, this Presentation is only addressed to and directed at persons (a) in member states of the European Economic Area ("EEA") who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129), as amended ("Qualified Investors") and (b), in the United Kingdom, who are "qualified investors" as defined in Regulation 2(e) of the UK Prospectus Regulation, who (i) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are other persons to whom this Presentation may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being referred to as "Relevant Persons"). The Presentation must not be acted or relied on (i) in the United Kingdom, by persons who are not Relevant Persons and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Save as set out above, any investment activity to which the Presentation relates is available only (i) in the United Kingdom, to Relevant Persons and (ii) in any member state of the EEA, to Qualified Investors, and may be engaged in only with persons. This Presentation does not constitute an offer or invitation for the sale or purchase of securities, or any businesses or assets described in it, nor does it purport to give legal, tax or financial advice. Nothing in the Presentation constitutes investment advice and any recommendations that may be contained therein have not been based upon a consideration of the investment objectives, financial situation or particular needs of any specific recipient. If you have received this Presentation and you are not a Relevant Person or a Qualified Investor you must return it immediately to the Company and not copy, reproduce or otherwise disclose

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this Presentation (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts ("NI 33-105"), BNPP and Peel Hunt are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

The Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to or acquire, securities of the Company, or an inducement to enter into investment activity in any country, and is not directed at persons in jurisdictions including the United States, Canada, Australia, Japan, South Africa, or in any other jurisdiction in which such offer, solicitation, inducement or sale would be unlawful prior to registration, unless an exemption under the relevant securities laws of such jurisdiction is applicable. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

The Presentation is not for publication, release or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken, transmitted or distributed, directly or indirectly into such jurisdiction. Any failure to comply with the foregoing restrictions may constitute a violation of United States or other national securities laws. You are required to inform yourself of, and comply with, all such restrictions and prohibitions and none of the Company, BNPP, Peel Hunt, their Associates nor any other person accepts liability to any person in relation thereto.

This Presentation, and any matter or dispute (whether contractual or non-contractual) arising out of it, shall be governed and construed in accordance with English law and the English courts shall have exclusive jurisdiction in relation to any such matter or dispute.